Featured Research

from universities, journals, and other organizations

The promise of DNA vaccines

Date:
April 22, 2010
Source:
Mary Ann Liebert, Inc./Genetic Engineering News
Summary:
Laboratory research and clinical studies are beginning to demonstrate that DNA vaccines can be as effective as traditional vaccines. A number of factors are driving the growth of the field, especially new approaches to electroporation, vaccine formulation, and vector design.

Laboratory research and clinical studies are beginning to demonstrate that DNA vaccines can be as effective as traditional vaccines, reports Genetic Engineering & Biotechnology News (GEN). A number of factors are driving the growth of the field, especially new approaches to electroporation, vaccine formulation, and vector design, according to the April 15 issue of GEN.

"A lot of development is focused on the creation of DNA vaccines for humans," says John Sterling, Editor in Chief of GEN. "Many of the advances being made are due to the introduction of new technologies and improvements in older methodologies."

For example, scientists at the Karolinska Institute and Tripep are working on a therapeutic vaccine for hepatitis C virus. A major impediment to successful DNA vaccination has been the failure to achieve sufficient uptake of the DNA by host tissue. This roadblock caused the collapse of a number of clinical trials a decade ago. The problems have now been resolved through improvements in transfection techniques, specifically electroporation. Inovio Biomedical, in particular, has aggressively pursued development of a minimally invasive electroporation device.

In addition, Althea Technologies has developed a high cell density fermentation and purification process for plasmid DNA products that reportedly provides plasmid yields in the range of 100-2,000 mg/L depending on plasmid size and bacterial strain. The company offers services in plasmid design and production, and possesses core capabilities in biological process development.

Also discussed in the GEN article is DNA vaccine-related work being carried out at BIA Separations, Nature Technology, the Walter Reed Army Research Institute, and VGXI.


Story Source:

The above story is based on materials provided by Mary Ann Liebert, Inc./Genetic Engineering News. Note: Materials may be edited for content and length.


Journal Reference:

  1. K. John Morrow Jr., Ph.D. DNA Vaccines Hit Their Stride with Approvals Anticipated. Genetic Engineering & Biotechnology News, Apr 15 2010 (Vol. 30, No. 8) [link]

Cite This Page:

Mary Ann Liebert, Inc./Genetic Engineering News. "The promise of DNA vaccines." ScienceDaily. ScienceDaily, 22 April 2010. <www.sciencedaily.com/releases/2010/04/100419132450.htm>.
Mary Ann Liebert, Inc./Genetic Engineering News. (2010, April 22). The promise of DNA vaccines. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/04/100419132450.htm
Mary Ann Liebert, Inc./Genetic Engineering News. "The promise of DNA vaccines." ScienceDaily. www.sciencedaily.com/releases/2010/04/100419132450.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins